VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
AZTRAzitra, Inc.
$0.16$2M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksAZTRBalance Sheet

Azitra, Inc. (AZTR) Balance Sheet

5Y historyFree accessUpdated daily

The balance sheet exhibits severe volatility, highlighted by a reported $12.1 billion in total assets for 2026Q1 that appears inconsistent with the firm's historical micro-cap scale.

AZTR Balance Sheet

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21
Total Current Assets10.76B3.02B5.23M2.54M4.14M8.49M
Cash & Short-Term Investments10.05B2.07B4.55M1.8M3.49M8.04M
Cash Only10.05B2.07B4.55M1.8M3.49M8.04M
Short-Term Investments000000
Accounts Receivable5.11M141.29K101.9K223.47K266.21K334.18K
Days Sales Outstanding--4.96118.9342.131.11K
Inventory000000
Days Inventory Outstanding------
Other Current Assets704.03M950.29M4.11K67.86K216.89K0
Total Non-Current Assets1.37B2.01B2.13M2.58M3.03M1.71M
Property, Plant & Equipment864.96M962.08M1.21M1.58M1.96M946.68K
Fixed Asset Turnover0.00x-6.22x0.43x0.14x0.12x
Goodwill000000
Intangible Assets334.52M316.67M246.42K210.88K219.57K97.69K
Long-Term Investments000000
Other Non-Current Assets167.18M727.31M678.22K789.99K848.34K668.23K
Total Assets12.13B5.03B7.36M5.12M7.17M10.2M
Asset Turnover0.00x-1.02x0.13x0.04x0.01x
Asset Growth %205078.68%68190.82%43.85%-28.63%-29.74%-
Total Current Liabilities1.55B1.07B1.38M1.6M2.22M1.21M
Accounts Payable932.22M399.36K490.25K897.27K784.69K717.8K
Days Payables Outstanding250.38K321.67----
Short-Term Debt246.59M265.89M0000
Deferred Revenue (Current)0000156K15K
Other Current Liabilities370.97M801.67M32.97K145.04K27.08K43.47K
Current Ratio6.94x2.83x3.80x1.58x1.86x7.02x
Quick Ratio6.94x2.83x3.80x1.58x1.86x7.02x
Cash Conversion Cycle------
Total Non-Current Liabilities96.74M156.19M284.65K599.14K41.21M34.76M
Long-Term Debt96.74M156.19M006.6M992.02K
Capital Lease Obligations645.64K0284.27K563.69K840.9K0
Deferred Tax Liabilities000000
Other Non-Current Liabilities0-156.19K38135.45K33.76M33.77M
Total Liabilities1.65B1.22B1.66M2.2M43.43M35.97M
Total Debt343.33M422.08M555.51K885.95K7.73M992.02K
Net Debt-9.71B-1.65B-4M-910.04K4.24M-7.05M
Debt / Equity0.03x0.11x0.10x0.30x--
Debt / EBITDA-30.25x-----
Net Debt / EBITDA855.45x-----
Interest Coverage-30.90x-1441.87x-735.72x-66.17x-41.40x-132.49x
Total Equity10.48B3.8B5.7M2.91M-36.26M-25.77M
Equity Growth %237600.37%66608.16%95.61%108.03%-40.73%-
Book Value per Share675.36779.9710.0484.40-599.41-425.93
Total Shareholders' Equity10.48B3.8B5.7M2.91M-36.26M-25.77M
Common Stock1.62M1.07K7631.21K104104
Retained Earnings-72.45B-68.52M-57.57M-48.6M-37.31M-26.63M
Treasury Stock000000
Accumulated OCI000000
Minority Interest000000

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Data integrity and liquidity

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Balance Sheet Stability Remains Elusive

As reported in financial statements, Azitra's asset base has exhibited extreme volatility, culminating in a reported $12.1 billion figure for 2026Q1 that deviates sharply from historical norms, suggesting significant data integrity concerns that complicate any assessment of the company's long-term financial trajectory or business quality.

The massive fluctuation in total assets and equity suggests that the company's balance sheet is not currently a reliable indicator of operational health. Investors should monitor whether these figures represent genuine capital restructuring or persistent reporting errors that obscure the firm's true financial standing.

Liquidity Position Obscured by Anomalies

Based on Azitra's reported figures, the current ratio has fluctuated wildly, reaching 6.94 in 2026Q1, which stands in stark contrast to the 0.77 ratio observed in 2024Q2, indicating that the company's ability to cover short-term obligations remains highly uncertain and potentially misrepresented in current filings.

The erratic nature of the cash position and current ratio suggests that the company may lack a stable buffer against operational shocks. Without consistent liquidity, the firm remains highly vulnerable to the need for dilutive financing to sustain its ongoing clinical development programs.

Equity Quality Diluted by Losses

According to recent SEC filings, the company's retained earnings have consistently trended downward, reaching a deficit of $72.4 billion in 2026Q1, which highlights the significant erosion of shareholder equity as the firm continues to fund its pre-revenue research and development activities through persistent capital consumption.

The accumulation of massive negative retained earnings underscores the high-risk nature of the company's business model. This trend suggests that shareholder value is being systematically depleted, and future recovery is entirely dependent on the successful clinical validation of its lead therapeutic candidates.

Data Integrity Risks Cloud Analysis

As indicated by the provided data, the reported $10.1 billion cash balance in 2026Q1 is fundamentally inconsistent with the company's micro-cap status, suggesting that the balance sheet may contain material reporting distortions that prevent an accurate evaluation of the firm's actual financial risk and operational runway.

The discrepancy between the reported cash and the company's historical burn rate warrants extreme skepticism from investors. Relying on these headline figures may lead to a fundamental misunderstanding of the company's true solvency and its immediate need for additional capital to continue operations.

AZTR — Frequently Asked Questions

Quick answers to the most common questions about buying AZTR stock.

What are the total assets of Azitra, Inc. (AZTR)?

As of 2025, Azitra, Inc. (AZTR) had total assets of $5.03B including $3.02B in current assets.

How much debt does Azitra, Inc. (AZTR) have?

Azitra, Inc. (AZTR) carries total debt of $422.1M, offset by $2.07B in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Azitra, Inc.?

Azitra, Inc. (AZTR) has total shareholders' equity (book value) of $3.80B ($779.97 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Azitra, Inc.'s current ratio and liquidity?

Azitra, Inc. (AZTR) reported a current ratio of 2.83x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.